My research activities are concentrated on cancer screening and early diagnosis. There is potential for considerable saving of lives from cancer if it were diagnosed at an earlier stage.
Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet (2017) 389:1299-1311. PMID: 28236467
Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. Lancet Oncol (2016) 17(1):109-14. PMID: 26655422
Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single arm FH01 study. Lancet Oncol (2010) 11: 1127-34. PMID: 21093374
Swedish Two-County Trial: impact of mammographic screening on breast cancer mortality during three decades. Radiol (2011) 260: 658-63. PMID: 21712474
2019-2023- NIHR, Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis, £5M
Radiological audit of interval breast cancers: Estimation of tumour growth rates MacInnes EG, Duffy SW, Simpson JA et al. Breast (2020) 51(7) 114-119
Early detection of breast cancer rectifies inequality of breast cancer outcomes. Tabár L, Chen TH-H, Yen AM-F et al. J Med Screen (2020) (2) 969141320921210
Lung Screen Uptake Trial (LSUT): Randomized Controlled Clinical Trial Testing Targeted Invitation Materials Quaife SL, Ruparel M, Dickson JL et al. American journal of respiratory and critical care medicine (2020) 201(7) 965-975
Tumour volume doubling times: clinicopathological factors that correlate with increased growth rates MacInnes EGE, Duffy SW, Simpson JA et al. BREAST CANCER RESEARCH AND TREATMENT (2020) 180(11) 555-555
Worldwide review and meta-analysis of cohort studies measuring the effect of mammography screening programmes on incidence-based breast cancer mortality Dibden A, Offman J, Duffy SW et al. Cancers (2020) 12(7)
Prevalence, Symptom Burden and Under-Diagnosis of Chronic Obstructive Pulmonary Disease in a Lung Cancer Screening Cohort. Ruparel M, Quaife SL, Dickson JL et al. Ann Am Thorac Soc (2020) (2)
Development of PancRISK, a urine biomarker-based risk score for stratified screening of pancreatic cancer patients Blyuss O, Zaikin A, Cherepanova V et al. British Journal of Cancer (2020) 122(7) 692-696
Errors in determination of net survival: cause-specific and relative survival settings Bright CJ, Brentnall AR, Wooldrage K et al. British Journal of Cancer (2020) (1)
Mortality reduction with low-dose CT screening for lung cancer Duffy SW, Field JK New England Journal of Medicine (2020) 382(7) 572-573
Sporadic implementation of UK familial mammographic surveillance guidelines 15 years after original publication Evans DG, Edwards M, Duffy SW et al. British Journal of Cancer (2020) 122(7) 329-332For additional publications, please click here
Oleg Blyuss, Amanda Dibden, Roberta Maroni, Daniel Vulkan
Senior Data Manager
I am a statistician by training, educated at the University of Edinburgh and Imperial College, London. I have worked in the UK, Singapore, France, Sweden and Russia.
For the last three decades, my research has been mainly in cancer epidemiology, prevention and screening. I worked on the pioneering Swedish Two-County Trial of breast cancer screening, on which the UK's national breast screening programme was based.
Since then I have taken a major role in a number of other trials of cancer screening, in breast, colorectal and lung cancer. These include the UK Trial of Flexible Sigmoidoscopy whose results changed national policy within weeks of publication, and the FH01 study of annual mammography in young women at enhanced familial risk of breast cancer, which contributed to the NICE guidelines on breast cancer risk management.
I am currently Director of the Policy Research Unit in Cancer Awareness, Screening and Early Diagnosis, funded by the Department of Health.
It is a collaboration between researchers from seven institutions (Queen Mary University of London, UCL, King's College London, London School of Hygiene and Tropical Medicine, Hull York Medical School, Durham University and Peninsula Medical School). The aim of the unit is to carry out research to inform policy to promote earlier diagnosis of cancer, symptomatically or by screening, and as a consequence bring down mortality from cancer.
In our strand of the Unit in Queen Mary University of London, our team concentrates on research aimed at evaluating cancer screening programmes, and devising innovations to these which will improve their effect on death from cancer, enhance their acceptability to the public and minimise side effects of screening, such as false positive rates.